

Checklist for healthcare professionals

At each treatment session, patients should be supervised during and after Spravato® (esketamine) nasal spray administration by a healthcare professional until they are stable, based on clinical judgement

The treating physician is responsible for deciding when the patient is considered clinically stable, based on this checklist and their clinical judgement, and therefore no longer requires to be monitored by a healthcare professional.

Clinical assessments

1. **Transient dissociative states and perception disorders (dissociation):** Have you confirmed that the patient does not have signs of dissociation or perceptual changes that might impair their functioning? ☐
2. **Disturbances in consciousness (sedation):** Have you confirmed that the patient is fully awake and responding to stimuli (i.e. not experiencing sedation)? ☐
3. **Blood pressure increased:** Are the patient's blood pressure values at acceptable levels? ☐
4. **Other adverse events:** Have any other adverse events resolved? ☐

The patient

5. If applicable, have you advised the patient that they should not drive or operate machinery until the next day following a restful sleep? ☐
6. If applicable, has the patient planned to travel home by public transport or arranged for someone else to drive them home? ☐


End of monitoring period

7. Do you, the treating physician, consider the patient is clinically stable and no longer requires to be monitored by a healthcare professional based on your clinical judgement? ☐



WARNING: If patients are not hospitalised, instruct them not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the day after Spravato® administration following restful sleep.

What to do in an emergency



Adverse events reporting guidance:

SFDA (National Pharmacovigilance center)

Email: npc.drug@sfd.gov.sa

Telephone: 19999

Online: <http://ade.sfd.gov.sa>



For full prescribing information, please refer to the datasheet or contact **Johnson & Johnson Trading Limited (Riyadh)**

Address: Prince Muhammed Bin Abdulaziz Rd, Tower B, Level 30, Olaya towers.

Office Tel 00966-11-4339133

Postal address: P O Box 65305 Riyadh 11556, Saudi Arabia

To report Adverse Events/Product Complaint or any Medical Information Inquiries, please contact us at:

Email: GCC-PV2@its.jnj.com Hotline:

00966540015811